Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.
The injection of bulking agents into the urethral submucosa is designed to create artificial urethral cushions that can improve urethral coaptation and hence restore continence. Ideally, a urethral bulking agent should be non-immunogenic and biocompatible, leading to minimal inflammatory and fibrotic response. The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite. To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.
Palma
Paulo C R
PC
Division of Urology, Campinas State University-UNICAMP, São Paulo, Brazil.
Riccetto
Cássio L Z
CL
Martins
Mario Henrique T
MH
Herrmann
Viviane
V
de Fraga
Rogerio
R
Billis
Athanase
A
Netto
Nelson Rodrigues
NR
D001672:Biocompatible Materials / Q000008:administration & dosage / Q000009:adverse effects*; D017886:Durapatite / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D015745:Granuloma, Foreign-Body / Q000150:complications* / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D009092:Mucous Membrane; D011391:Prolapse; D014521:Urethra; D014522:Urethral Diseases / Q000209:etiology*; D014550:Urinary Incontinence, Stress / Q000188:drug therapy*
D001672:Biocompatible Materials; D017886:Durapatite